Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension

Inclusion Criteria:

• 18 - 85 years of age willing and able to give informed consent and in theinvestigator's judgment able to follow the study protocol
• Ocular hypertension, primary open-angle glaucoma, pigmentary or pseudoexfoliationglaucoma, with mild to moderate glaucoma defined as Mean Deviation on Humphrey VisualField testing no worse than -10 dB
• Patients on latanoprost in the study eye with an adequate IOP control with latanoprostalone

Exclusion Criteria: Systemic

• Use of oral carbonic anhydrase inhibitors
• Unstable dose of oral medication during the last 30 days that in the opinion of theInvestigator may influence the IOP
• Unstable dose of oral steroid at the time of enrollment
• Use of immunosuppressants, immunomodulators, antimetabolites and/or alkylating agentswithin six months before screening or anticipated use at any time during the study
• Known allergy or hypersensitivity to the study medication or its components
• Female patients who are pregnant, nursing, or planning a pregnancy, or who are ofchildbearing potential and not using a reliable means of contraception
• Participation in an investigational drug or device study within the 30 days beforescreening
• Patient has a condition or is in a situation which, in the Investigator's opinion, mayput the patient at significant risk, may confound the study results, or may interferesignificantly with the patient's participation in the study
• Any condition (including the inability to read visual acuity charts or languagebarrier) which precludes a patient's ability to comply with study requirementsincluding completion of the study Study Eye
• History of complex cataract surgery with vitreous loss
• History of cystoid macular edema or uveitis
• Corneal decompensation or edema
• Corneal thickness <500 or > 600 μm in the study eye by pachymetry
• Prior treatment-related adverse event or allergy to latanoprost
• Evidence of macular edema/intraretinal fluid on screening macula optical coherencetomography (OCT)
• Any ocular condition in the study eye that in the opinion of the investigator wouldprevent the eye from wearing a contact lens (e.g., ectropion, lid abnormality, orsymblepharon)
• Use of beta-blocker, alpha agonist, rho kinase inhibitor, or carbonic anhydraseinhibitor drops within 1 month prior to screening; the use of latanoprost must bestable for at least 4 weeks prior to screening
• Use of latanoprost for < 4 weeks prior to screening
• Use of topical steroids
• Active optic disc or retinal neovascularization in the study eye at screening
• Presence of rubeosis iridis in the study eye at screening
• History of herpetic infection in the study eye or adnexa
• Media opacity in the study eye at screening that precludes clinical and photographicevaluation (including but not limited to preretinal or vitreous hemorrhage, lensopacity)
• Intraocular surgery, including cataract surgery, and/or laser of any type in the studyeye within 30 days prior to screening
• History of kerato-refractive surgery
• Any prior filtering surgery, including trabeculectomy, glaucoma drainage device, orXen implant
• Inability to comfortably wear a commercial contact lens (C-CL) that has the samedimensions as the L-CL during the week-long run-in period Both Eyes: any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) ineither eye at screening Non-study Eye: Pinhole score < 19 letters (at least 20/400 Snellen equivalent) in thenon-study eye at the screening visit